Jianxiang Wang, Doctor
Institute of Hematology and Blood Disease Hospital · Hospital of Blood Disease, Chinese Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianxiang Wang, Doctor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:15 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04402723 · Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLSuzhou Zelgen Biopharmaceuticals Co.,Ltd · terminated · Acute Myeloid Leukemia (AML) · principal investigator
- Ph1NCT03125876 · A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)Sunshine Lake Pharma Co., Ltd. · terminated · Acute Myeloid Leukemia (AML) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.